|
Oct 2
|
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
|
|
Sep 26
|
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
|
|
Jul 29
|
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
|
|
Jul 23
|
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
|
|
Jun 27
|
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
|
|
Jun 25
|
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
|
|
Jun 12
|
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
|
|
Jun 10
|
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
|
|
Apr 22
|
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
|
|
Apr 12
|
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
|
|
Mar 28
|
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
|
|
Mar 20
|
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
|
|
Mar 14
|
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
|
|
Mar 8
|
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
|
|
Mar 7
|
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
|
|
Mar 4
|
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
|
|
Jan 10
|
ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms
|
|
Dec 19
|
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call Transcript
|
|
Dec 8
|
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
|
|
Dec 7
|
ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14
|